Adlai Nortye Ltd. (ANL) Insider Trading Activity

Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Show less

Over the last 12 months, insiders at Adlai Nortye Ltd. have bought $0 and sold $0 worth of Adlai Nortye Ltd. stock.

On average, over the past 5 years, insiders at Adlai Nortye Ltd. have bought $0 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 8,700 shares for transaction amount of $168,717 was made by RHODES THOMAS L (director) on 2004‑09‑27.